CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that eligible patients in Ontario now have ...

Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of province's cancer ...

But there are other more specialist uses, such as using the radioactive Lutetium-177 isotope in cancer therapy. Lutetium ions were also used to dope gadolinium gallium garnet to make magnetic bubble ...

Phase 2 Trial - A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (TheraP) Phase 2 Trial - Lutetium-177 (Lu177) Prostate-Specific ...

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of Ontario’s Cancer ...

BRCA- and tumor suppressor gene mutations are associated with worse overall survival among patients receiving lutetium-177 PSMA radioligand therapy for mCRPC. Lutetium-177-PMSA radioligand therapy ...

It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify patients for whom PSMA-targeted therapy with (177 Lu)lutetium vipivotide ...

Operator Eletronuclear and the Brazilian Society of Nuclear Medicine have signed an agreement aimed at producing ...

New consensus recommendations address implementation of novel treatments and imaging techniques for advanced and ...